BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
BioAtla (BCAB) has announced two poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase the company's proprietary Conditionally Active Biologic (CAB) technology.
The first poster demonstrates CAB anti-Nectin4-antibody drug conjugate's superior efficacy compared to enfortumab vedotin analogue in multiple cancer models. The second presentation focuses on novel senolytic targets and CAB-based drug conjugates for targeting senescence-associated secretory phenotype cells.
The presentations will be held on April 27 and April 28, 2025, featuring research by authors including Jian Chen, Jing Wang, and others. The CAB technology aims to provide a new generation of biologics with improved safety margins and therapeutic index, specifically targeting acidic senescence in cancer and age-related diseases.
BioAtla (BCAB) ha annunciato due presentazioni poster al prossimo Meeting Annuale 2025 dell'American Association for Cancer Research (AACR) che si terr脿 a Chicago dal 25 al 30 aprile 2025. Le presentazioni metteranno in evidenza la tecnologia proprietaria dell'azienda, il Conditionally Active Biologic (CAB).
Il primo poster dimostra l'efficacia superiore del coniugato anticorpo-farmaco anti-Nectin4 basato su CAB rispetto all'analogo di enfortumab vedotin in diversi modelli tumorali. La seconda presentazione si concentra su nuovi target senolitici e coniugati farmacologici basati su CAB per colpire le cellule con fenotipo secretorio associato alla senescenza.
Le presentazioni si terranno il 27 e 28 aprile 2025 e includeranno ricerche di autori come Jian Chen, Jing Wang e altri. La tecnologia CAB mira a offrire una nuova generazione di biologici con margini di sicurezza e indice terapeutico migliorati, mirati specificamente alla senescenza acida nel cancro e nelle malattie legate all'et脿.
BioAtla (BCAB) ha anunciado dos presentaciones en formato p贸ster en la pr贸xima Reuni贸n Anual 2025 de la Asociaci贸n Americana para la Investigaci贸n del C谩ncer (AACR) que se celebrar谩 en Chicago del 25 al 30 de abril de 2025. Las presentaciones mostrar谩n la tecnolog铆a patentada de la compa帽铆a, el Conditionally Active Biologic (CAB).
El primer p贸ster demuestra la eficacia superior del conjugado anticuerpo-f谩rmaco anti-Nectin4 basado en CAB en comparaci贸n con un an谩logo de enfortumab vedotin en m煤ltiples modelos de c谩ncer. La segunda presentaci贸n se centra en nuevos objetivos senol铆ticos y conjugados farmacol贸gicos basados en CAB para atacar las c茅lulas con fenotipo secretor asociado a la senescencia.
Las presentaciones se llevar谩n a cabo el 27 y 28 de abril de 2025, con investigaciones de autores como Jian Chen, Jing Wang y otros. La tecnolog铆a CAB busca ofrecer una nueva generaci贸n de biol贸gicos con m谩rgenes de seguridad mejorados e 铆ndice terap茅utico, dirigidos espec铆ficamente a la senescencia 谩cida en el c谩ncer y enfermedades relacionadas con la edad.
BioAtla (BCAB)電� 2025雲� 4鞗� 25鞚茧秬韯� 30鞚缄箤歆� 鞁滌勾瓿犾棎靹� 鞐措Μ電� 2025 氙戈淡鞎旍棸甑暀須�(AACR) 鞐半須岇潣鞐愳劀 霊� 瓯挫潣 韽姢韯� 氚滍憸毳� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 氚滍憸鞐愳劀電� 須岇偓鞚� 霃呾瀽鞝侅澑 臁瓣贝攵� 頇滌劚 靸濍頃欖爜 鞝滌牅(CAB) 旮办垹鞚� 靹犽炒鞛呺媹雼�.
觳� 氩堨Ц 韽姢韯半姅 CAB 旮半皹鞚� anti-Nectin4 頃泊-鞎诫 鞝戫暕觳搓皜 鞐煬 鞎� 氇嵏鞐愳劀 enfortumab vedotin 鞙犾偓觳措炒雼� 鞖办垬頃� 須姤鞚� 氤挫瀯鞚� 鞛呾頃╇媹雼�. 霊� 氩堨Ц 氚滍憸電� 雲疙檾 甏�霠� 攵勲箘順� 響滍槃順� 靹疙彫毳� 響滌爜頃橂姅 靸堧鞖� 靹鸽唨毽嫳 響滌爜瓿� CAB 旮半皹 鞎诫 鞝戫暕觳挫棎 齑堨爯鞚� 毵烄顶雼堧嫟.
氚滍憸電� 2025雲� 4鞗� 27鞚缄臣 28鞚检棎 歆勴枆霅橂┌, Jian Chen, Jing Wang 霌� 鞐瓣惮歆勳澊 彀胳棳頃╇媹雼�. CAB 旮办垹鞚� 鞎旉臣 雲疙檾 甏�霠� 歆堩櫂鞐愳劀 靷办劚 雲疙檾毳� 韸轨澊鞝侅溂搿� 響滌爜頃橃棳 鞎堨爠靹� 頃滉硠鞕� 旃橂 歆�靾橂ゼ 臧滌劆頃� 彀劯雽� 靸濍頃欖爜 鞝滌牅毳� 鞝滉车頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
BioAtla (BCAB) a annonc茅 deux pr茅sentations sous forme de posters lors de la prochaine R茅union Annuelle 2025 de l'American Association for Cancer Research (AACR) qui se tiendra 脿 Chicago du 25 au 30 avril 2025. Ces pr茅sentations mettront en lumi猫re la technologie propri茅taire de l'entreprise, le Conditionally Active Biologic (CAB).
Le premier poster d茅montre l'efficacit茅 sup茅rieure du conjugu茅 anticorps-m茅dicament anti-Nectin4 bas茅 sur CAB compar茅 脿 un analogue de l'enfortumab vedotin dans plusieurs mod猫les tumoraux. La seconde pr茅sentation porte sur de nouvelles cibles s茅nolytiques et des conjugu茅s m茅dicamenteux bas茅s sur CAB pour cibler les cellules pr茅sentant un ph茅notype s茅cr茅toire associ茅 脿 la s茅nescence.
Les pr茅sentations auront lieu les 27 et 28 avril 2025 et pr茅senteront des recherches men茅es par des auteurs tels que Jian Chen, Jing Wang et d'autres. La technologie CAB vise 脿 offrir une nouvelle g茅n茅ration de biologiques avec une meilleure marge de s茅curit茅 et un indice th茅rapeutique am茅lior茅, ciblant sp茅cifiquement la s茅nescence acide dans le cancer et les maladies li茅es 脿 l'芒ge.
BioAtla (BCAB) hat zwei Posterpr盲sentationen auf dem bevorstehenden Jahrestreffen 2025 der American Association for Cancer Research (AACR) angek眉ndigt, das vom 25. bis 30. April 2025 in Chicago stattfindet. Die Pr盲sentationen werden die firmeneigene Conditionally Active Biologic (CAB)-Technologie vorstellen.
Das erste Poster zeigt die 眉berlegene Wirksamkeit des CAB-basierten Anti-Nectin4-Antik枚rper-Wirkstoff-Konjugats im Vergleich zu einem Enfortumab Vedotin-Analogon in mehreren Krebsmodellen. Die zweite Pr盲sentation konzentriert sich auf neuartige senolytische Targets und CAB-basierte Wirkstoffkonjugate zur gezielten Bek盲mpfung von Zellen mit seneszenz-assoziiertem sekretorischem Ph盲notyp.
Die Pr盲sentationen finden am 27. und 28. April 2025 statt und umfassen Forschungen von Autoren wie Jian Chen, Jing Wang und weiteren. Die CAB-Technologie zielt darauf ab, eine neue Generation von Biologika mit verbesserten Sicherheitsprofilen und therapeutischem Index bereitzustellen, die speziell saure Seneszenz bei Krebs und altersbedingten Erkrankungen anvisieren.
- None.
- None.
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) to be held at the McCormick Place Convention Center in Chicago, IL from April 25鈥�30, 2025.听
- Two abstracts accepted for poster presentation highlight Company鈥檚 proprietary Conditionally Active Biologic (CAB) technology
- Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in lung, breast, pancreatic and urothelial patient derived cancer models
- CAB technology provides a new generation of biologics with an increased safety margin and therapeutic index, selectively targeting acidic senescence and senescence-associated secretory phenotype cells in cancer and age-related diseases
Presentation Details:
| Poster Title: | Identification of novel senolytic targets and development of Conditionally Active Biologic-based-drug conjugates for targeted senescence-associated secretory phenotype elimination听in vivo |
| Authors: | Jian Chen, Jing Wang, Haizhen Liu, Gerhard Frey, Cathy Chang, William J. Boyle, and Jay M. Short |
| Poster Number: | 5 |
| Session Category / Title: | Molecular/Cellular Biology and Genetics / Senescence |
| Date / Time: | Sunday, April 27, 2025; 2:00鈥�5:00 PM CDT |
| Location: | Poster Section 13 |
| 听 | 听 |
| Poster Title: | BA3361, A Tumor Selective, Conditionally Active Biologic (CAB) anti-Nectin4-ADC with a Novel NextGen Linker System Enhances Therapeutic Efficacy in Pancreatic Cancer |
| Authors: | Jing Wang, Jian Chen, Gerhard Frey, Haizhen Liu, Charles Xing, Kathryn Woodard, Cathy Chang, William J. Boyle, and Jay M. Short |
| Poster Number: | 10 |
| Session Category / Title: | Tumor Biology / Targeting the Tumor Microenvironment: A Brave New World |
| Date / Time: | Monday, April 28, 2025; 2:00鈥�5:00 PM CDT |
| Location: | Poster Section 7 |
| 听 | 听 |
A copy of the presentation materials can be accessed on the 鈥溾�� section of the Company鈥檚 website at once the presentations have concluded.
About BioAtla庐, Inc.听
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets includes methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla鈥檚 first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit听.
Internal Contact:听
Richard Waldron听
Chief Financial Officer听
BioAtla, Inc.听
858.356.8945听
External Contact:听
Bruce Mackle
LifeSci Advisors, LLC
听
FAQ
What are the key findings of BioAtla's (BCAB) CAB technology presentations at AACR 2025?
When and where will BioAtla (BCAB) present their research at AACR 2025?
What cancer types does BioAtla's (BCAB) CAB anti-Nectin4-ADC show efficacy against?
How does BioAtla's (BCAB) Conditionally Active Biologic technology improve cancer treatment?
